Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization.
about
Fluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsImmune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brainsNeuroinflammation in Alzheimer's diseaseR47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological StudyTargeting neuroinflammation in Alzheimer's diseaseNeuroinflammation in Alzheimer's diseaseInteractions between inflammation, sex steroids, and Alzheimer's disease risk factorsReprogramming of HUVECs into induced pluripotent stem cells (HiPSCs), generation and characterization of HiPSC-derived neurons and astrocytesReceptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.Microglia of prefrontal white matter in suicideAmyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect.A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortexPost-mortem analysis of neuroinflammatory changes in human Alzheimer's disease.RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.APOE Stabilization by Exercise Prevents Aging Neurovascular Dysfunction and Complement Induction.Young microglia restore amyloid plaque clearance of aged microglia.Progesterone treatment reduces neuroinflammation, oxidative stress and brain damage and improves long-term outcomes in a rat model of repeated mild traumatic brain injury.Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease.Microglial immunophenotype in dementia with Alzheimer's pathology.The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradationAPOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice.Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.Biomarker modelling of early molecular changes in Alzheimer's disease.Alzheimer disease and cellular mechanisms of memory storage.New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease.Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment.Central nervous system myeloid cells as drug targets: current status and translational challenges.Does the Interplay Between Aging and Neuroinflammation Modulate Alzheimer's Disease Clinical Phenotypes? A Clinico-Pathological Perspective.Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model.Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathyHippocampal proteomics defines pathways associated with memory decline and resilience in normal aging and Alzheimer's disease mouse models.Innate immunity in Alzheimer's disease: the relevance of animal models?Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury.Ginsenoside Rg1 protects against neuronal degeneration induced by chronic dexamethasone treatment by inhibiting NLRP-1 inflammasomes in mice.Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline.Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology.
P2860
Q26784569-074799EE-9B11-4459-937F-33B7F5461C3AQ26796857-9010104F-BB31-4939-A433-19A9B03AD290Q27004226-A7538B37-3DBD-4240-97BC-3C426BCB7966Q27345528-46744893-B667-4072-818F-93EE16837CD1Q28078474-D6F87DB7-AD8F-4406-B76D-2B38DC074D85Q28259238-7CB28F6F-D381-4EF3-9560-7C91B774BD63Q28394967-FF68C84D-29BC-4010-8CD7-60F21245BBAFQ28544716-F035E01C-1C49-4FB2-BDCE-F253D113B317Q33887359-8279AA49-0354-42C0-844F-5D62D388C21AQ34076322-74734B67-1267-4BC6-90E2-F17DA47A76D4Q34227162-11EAEA46-87E1-4FFA-B81D-47C9AF00FE68Q34376103-F7F424D8-2854-4257-861E-3D7AF5B57AE5Q34460952-93171BE5-E66C-4813-AC75-7D3E13E632B7Q34518856-E7531686-4ED2-4E0B-AEDC-A2497CB29C74Q35044486-E04E0044-BA6E-4560-851E-80760E7E064EQ35519004-A10F3E72-25C8-4A95-8C61-ADCA6FFC35F2Q35662879-FF7C8974-B5E4-4DFE-B23D-29FA443F83B3Q35825824-78F6747E-2DBC-4F48-89F4-773FF82C3CB0Q36231976-D516B7CB-6F0D-4889-BDAF-01650E1EA5CCQ36384042-1CAD2021-407B-4CBB-8B3F-D612E1807A42Q36509219-4AD9D8C2-E208-439B-8C56-1BA86E098A17Q36960714-3905B328-FCFB-49D7-82D9-2FA15457EAA0Q37085168-BF966CCA-2CAF-4731-963A-EA851369C5A4Q37615879-36C0B802-6F09-4F63-BCC7-CEC86A83E02FQ37630548-4893E2A4-9AED-4E01-818D-4E9AC895293DQ38166669-88D0F414-E260-4B4D-B6F4-610569C52DA9Q38184387-E6EC63CD-EB80-475B-9626-B19B941B1C7AQ38246262-1316BF90-0A42-4562-ADA0-2ABB73BDBA33Q38657074-2349A8D3-E951-4C6D-825D-30A068566AD6Q38658658-90690A66-C86F-475B-AF18-09902A064961Q38833716-40B741EC-EA9C-4788-B920-BACE4F2A946AQ39136356-532CFADF-D2AE-4274-B023-331AEEC2D990Q39210948-C64AD400-2C7C-47DD-A3BF-CA6A6C827AE3Q39292060-6776B09C-0C29-4BF5-B36A-46199C42A0CAQ39314130-20554B76-641A-4372-A775-35FED84C4A10Q39320824-886107D4-C716-4E2E-B9EC-69785089E2F0Q41170285-1C2D315C-64BB-4161-A2FF-07D5D9453B23Q41351880-D6281A03-2B0B-4FFE-B64B-922152B5DF58Q41387476-4665A7CC-1BDC-48F0-A38E-2030F9EBA405Q42683481-63115D55-777F-4130-B3DD-A6C3BDBAE21E
P2860
Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Inflammatory components in hum ...... tive amyloid-β42 immunization.
@en
Inflammatory components in hum ...... tive amyloid-β42 immunization.
@nl
type
label
Inflammatory components in hum ...... tive amyloid-β42 immunization.
@en
Inflammatory components in hum ...... tive amyloid-β42 immunization.
@nl
prefLabel
Inflammatory components in hum ...... tive amyloid-β42 immunization.
@en
Inflammatory components in hum ...... tive amyloid-β42 immunization.
@nl
P2093
P2860
P356
P1433
P1476
Inflammatory components in hum ...... tive amyloid-β42 immunization.
@en
P2093
Elina Zotova
James A R Nicoll
James W Neal
Matthew Cheaveau
Scott Harris
Viraj Bharambe
William Morgan
P2860
P304
P356
10.1093/BRAIN/AWT210
P407
P577
2013-08-13T00:00:00Z